Kaposi Sarcoma-associated Herpesvirus: Immunobiology, Oncogenesis, and Therapy

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2016 Sep 2

PMID 27584730

Citations 112

Authors

Dirk P Dittmer

Blossom Damania

Affiliations

Soon will be listed here.

Abstract

Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8, is the etiologic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. This human gammaherpesvirus was discovered in 1994 by Drs. Yuan Chang and Patrick Moore. Today, there are over five thousand publications on KSHV and its associated malignancies. In this article, we review recent and ongoing developments in the KSHV field, including molecular mechanisms of KSHV pathogenesis, clinical aspects of KSHV-associated diseases, and current treatments for cancers associated with this virus.

Citing Articles

Population Genetic Structure and Human Adaptation of Kaposi Sarcoma-Associated Herpesvirus.

Mozzi A, Forni D, Cagliani R, Molteni C, Clerici M, Sironi M Open Forum Infect Dis. 2025; 12(3):ofaf111.

PMID: 40078966 PMC: 11896972. DOI: 10.1093/ofid/ofaf111.

The 'Oma's of the Gammas-Cancerogenesis by γ-Herpesviruses.

Banerjee A, Dass D, Mukherjee S, Kaul M, Harshithkumar R, Bagchi P Viruses. 2025; 16(12.

PMID: 39772235 PMC: 11680331. DOI: 10.3390/v16121928.

Microneedle-Array-Mediated Transdermal Delivery of GCV-Functionalized Zeolitic Imidazolate Framework-8 Nanoparticles for KSHV Treatment.

Liu C, Yin X, Xu H, Xu J, Gong M, Li Z Int J Mol Sci. 2024; 25(23).

PMID: 39684656 PMC: 11641177. DOI: 10.3390/ijms252312946.

Tumor-Associated Edema in Children with Kaposi Sarcoma: 14 Years' Experience at Kamuzu Central Hospital, Lilongwe, Malawi.

Manase F, Silverstein A, Kamiyango W, Villiera J, Dziwe C, Wallrauch C Cancers (Basel). 2024; 16(22).

PMID: 39594724 PMC: 11592151. DOI: 10.3390/cancers16223769.

Virus-modified paraspeckle-like condensates are hubs for viral RNA processing and their formation drives genomic instability.

Harper K, Harrington E, Hayward C, Anene C, Wongwiwat W, White R Nat Commun. 2024; 15(1):10240.

PMID: 39592606 PMC: 11599752. DOI: 10.1038/s41467-024-54592-5.

References

Wang L, Damania B . Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res. 2008; 68(12):4640-8. PMC: 2612117. DOI: 10.1158/0008-5472.CAN-07-5988. View

Gantt S, Cattamanchi A, Krantz E, Magaret A, Selke S, Kuntz S . Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol. 2014; 60(2):127-32. PMC: 4020979. DOI: 10.1016/j.jcv.2014.03.002. View

Lee M, Jones T, Song D, Jang J, Jung J, Gao S . Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infection. PLoS Pathog. 2014; 10(9):e1004412. PMC: 4177982. DOI: 10.1371/journal.ppat.1004412. View

Wu W, Vieira J, Fiore N, Banerjee P, Sieburg M, Rochford R . KSHV/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: persistence of infection during hematopoiesis in vitro and in vivo. Blood. 2006; 108(1):141-51. PMC: 1895828. DOI: 10.1182/blood-2005-04-1697. View

Krown S, Borok M, Campbell T, Casper C, Dittmer D, Hosseinipour M . Stage-stratified approach to AIDS-related Kaposi's sarcoma: implications for resource-limited environments. J Clin Oncol. 2014; 32(23):2512-3. PMC: 4809749. DOI: 10.1200/JCO.2014.55.8999. View

Stebbing J, Bourboulia D, Johnson M, Henderson S, Williams I, Wilder N . Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. J Virol. 2003; 77(7):4306-14. PMC: 150628. DOI: 10.1128/jvi.77.7.4306-4314.2003. View

Prasad A, Lu M, Lukac D, Zeichner S . An alternative Kaposi's sarcoma-associated herpesvirus replication program triggered by host cell apoptosis. J Virol. 2012; 86(8):4404-19. PMC: 3318647. DOI: 10.1128/JVI.06617-11. View

Mbulaiteye S, Marshall V, Bagni R, Wang C, Mbisa G, Bakaki P . Molecular evidence for mother-to-child transmission of Kaposi sarcoma-associated herpesvirus in Uganda and K1 gene evolution within the host. J Infect Dis. 2006; 193(9):1250-7. DOI: 10.1086/503052. View

Scehnet J, Ley E, Krasnoperov V, Liu R, Manchanda P, Sjoberg E . The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood. 2008; 113(1):254-63. PMC: 2614637. DOI: 10.1182/blood-2008-02-140020. View

10.

Lingel A, Ehlers E, Wang Q, Cao M, Wood C, Lin R . Kaposi's Sarcoma-Associated Herpesvirus Reduces Cellular Myeloid Differentiation Primary-Response Gene 88 (MyD88) Expression via Modulation of Its RNA. J Virol. 2015; 90(1):180-8. PMC: 4702530. DOI: 10.1128/JVI.02342-15. View

11.

Hahn A, Kaufmann J, Wies E, Naschberger E, Panteleev-Ivlev J, Schmidt K . The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirus. Nat Med. 2012; 18(6):961-6. PMC: 3645317. DOI: 10.1038/nm.2805. View

12.

Ngo V, Young R, Schmitz R, Jhavar S, Xiao W, Lim K . Oncogenically active MYD88 mutations in human lymphoma. Nature. 2010; 470(7332):115-9. PMC: 5024568. DOI: 10.1038/nature09671. View

13.

Hellert J, Weidner-Glunde M, Krausze J, Richter U, Adler H, Fedorov R . A structural basis for BRD2/4-mediated host chromatin interaction and oligomer assembly of Kaposi sarcoma-associated herpesvirus and murine gammaherpesvirus LANA proteins. PLoS Pathog. 2013; 9(10):e1003640. PMC: 3798688. DOI: 10.1371/journal.ppat.1003640. View

14.

Ishido S, Wang C, Lee B, COHEN G, Jung J . Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol. 2000; 74(11):5300-9. PMC: 110885. DOI: 10.1128/jvi.74.11.5300-5309.2000. View

15.

Sodhi A, Chaisuparat R, Hu J, Ramsdell A, Manning B, Sausville E . The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell. 2006; 10(2):133-43. DOI: 10.1016/j.ccr.2006.05.026. View

16.

Rahim Rezaee S, Gracie J, McInnes I, Blackbourn D . Inhibition of neutrophil function by the Kaposi's sarcoma-associated herpesvirus vOX2 protein. AIDS. 2005; 19(16):1907-10. DOI: 10.1097/01.aids.0000189849.75699.46. View

17.

Sin S, Roy D, Wang L, Staudt M, Fakhari F, Patel D . Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood. 2006; 109(5):2165-73. PMC: 1801055. DOI: 10.1182/blood-2006-06-028092. View

18.

Bower M, Dalla Pria A, Coyle C, Andrews E, Tittle V, Dhoot S . Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma. J Clin Oncol. 2014; 32(5):409-14. DOI: 10.1200/JCO.2013.51.6757. View

19.

Barbera A, Chodaparambil J, Kelley-Clarke B, Joukov V, Walter J, Luger K . The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science. 2006; 311(5762):856-61. DOI: 10.1126/science.1120541. View

20.

Mboko W, Olteanu H, Ray A, Xin G, Darrah E, Kumar S . Tumor Suppressor Interferon-Regulatory Factor 1 Counteracts the Germinal Center Reaction Driven by a Cancer-Associated Gammaherpesvirus. J Virol. 2016; 90(6):2818-29. PMC: 4810652. DOI: 10.1128/JVI.02774-15. View